173 related articles for article (PubMed ID: 9532519)
1. Stepped care for hypertension: are the assumptions valid?
Caro JJ
J Hypertens Suppl; 1997 Dec; 15(7):S35-9. PubMed ID: 9532519
[TBL] [Abstract][Full Text] [Related]
2. Antihypertensive persistence and drug class.
Marentette MA; Gerth WC; Billings DK; Zarnke KB
Can J Cardiol; 2002 Jun; 18(6):649-56. PubMed ID: 12107422
[TBL] [Abstract][Full Text] [Related]
3. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data.
Caro JJ; Speckman JL; Salas M; Raggio G; Jackson JD
CMAJ; 1999 Jan; 160(1):41-6. PubMed ID: 9934342
[TBL] [Abstract][Full Text] [Related]
4. Persistence with treatment in newly treated middle-aged patients with essential hypertension.
Perreault S; Lamarre D; Blais L; Dragomir A; Berbiche D; Lalonde L; Laurier C; St-Maurice F; Collin J
Ann Pharmacother; 2005 Sep; 39(9):1401-8. PubMed ID: 16076920
[TBL] [Abstract][Full Text] [Related]
5. Long-term persistence with antihypertensive drugs in new patients.
Degli Esposti E; Sturani A; Di Martino M; Falasca P; Novi MV; Baio G; Buda S; Volpe M
J Hum Hypertens; 2002 Jun; 16(6):439-44. PubMed ID: 12037702
[TBL] [Abstract][Full Text] [Related]
6. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study.
Bourgault C; Sénécal M; Brisson M; Marentette MA; Grégoire JP
J Hum Hypertens; 2005 Aug; 19(8):607-13. PubMed ID: 15920457
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in ontario.
Friedman O; McAlister FA; Yun L; Campbell NR; Tu K;
Am J Med; 2010 Feb; 123(2):173-81. PubMed ID: 20103027
[TBL] [Abstract][Full Text] [Related]
8. Antihypertensive drug prescription trends at the primary health care centres in Bahrain.
Jassim al Khaja KA; Sequeira RP; Wahab AW; Mathur VS
Pharmacoepidemiol Drug Saf; 2001 May; 10(3):219-27. PubMed ID: 11501335
[TBL] [Abstract][Full Text] [Related]
9. Persistence with treatment for hypertension in actual practice.
Caro JJ; Salas M; Speckman JL; Raggio G; Jackson JD
CMAJ; 1999 Jan; 160(1):31-7. PubMed ID: 9934341
[TBL] [Abstract][Full Text] [Related]
10. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study.
Erkens JA; Panneman MM; Klungel OH; van den Boom G; Prescott MF; Herings RM
Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):795-803. PubMed ID: 16178043
[TBL] [Abstract][Full Text] [Related]
11. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
[TBL] [Abstract][Full Text] [Related]
12. Blood pressure and serum potassium levels in hypertensive patients receiving or not receiving antihypertensive treatment.
Pikilidou MI; Lasaridis AN; Sarafidis PA; Tziolas IM; Zebekakis PE; Dombros NV; Giannoulis E
Clin Exp Hypertens; 2007 Nov; 29(8):563-73. PubMed ID: 18058481
[TBL] [Abstract][Full Text] [Related]
13. Contemporary practice patterns in the management of newly diagnosed hypertension.
McAlister FA; Teo KK; Lewanczuk RZ; Wells G; Montague TJ
CMAJ; 1997 Jul; 157(1):23-30. PubMed ID: 9220938
[TBL] [Abstract][Full Text] [Related]
14. Existing treatment strategies: does noncompliance make a difference?
Caro JJ; Speckman JL
J Hypertens Suppl; 1998 Sep; 16(7):S31-4. PubMed ID: 9855029
[TBL] [Abstract][Full Text] [Related]
15. Uptake of angiotensin II receptor blockers in the treatment of hypertension.
Greving JP; Denig P; van der Veen WJ; Beltman FW; Sturkenboom MC; de Zeeuw D; Haaijer-Ruskamp FM
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):461-6. PubMed ID: 15912393
[TBL] [Abstract][Full Text] [Related]
16. Antihypertensive drug-associated sexual dysfunction: a prescription analysis-based study.
al Khaja KA; Sequeira RP; al Damanhori AH; Mathur VS
Pharmacoepidemiol Drug Saf; 2003; 12(3):203-12. PubMed ID: 12733473
[TBL] [Abstract][Full Text] [Related]
17. Trends in antihypertensive and lipid-lowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?
Gulliford MC; Charlton J; Latinovic R
J Hum Hypertens; 2005 Feb; 19(2):111-7. PubMed ID: 15361893
[TBL] [Abstract][Full Text] [Related]
18. Persistence with hypertension treatment among community-dwelling BC seniors.
Morgan SG; Yan L
Can J Clin Pharmacol; 2004; 11(2):e267-73. PubMed ID: 15596883
[TBL] [Abstract][Full Text] [Related]
19. [Influence of risk factors and pharmacological treatment on mortality in patients with essential hypertension].
Román O; Cuevas G; Bunout D
Rev Med Chil; 1998 Jul; 126(7):745-52. PubMed ID: 9830766
[TBL] [Abstract][Full Text] [Related]
20. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
